期刊
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
卷 10, 期 4, 页码 695-706出版社
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2014.1830
关键词
Survivin; Melittin; Hepatocellular Carcinoma
资金
- National Natural Science Foundation of China [30972913]
- Natural Science Foundation of Jiangsu province of China [BK2009451]
- Science and Technology Development Projects of Nanjing [201104029]
- Medical Key Talent Foundation of Jiangsu Province [RC2011081]
- Medical Key Science and Technology Development Projects of Nanjing [ZKX11176]
Hepatic resection and orthotopic liver transplantation are the only potentially curative treatments for hepatocellular carcinoma (HCC) but are indicated only in a minority of patients. Biosynthetic nanoscale peptide Melittin (Mel) is postulated to disrupt microbial phospholipid membranes by formation of stable or transient pores. Survivin, a member of the inhibitor of apoptosis family, is transcriptionally upregulated in most malignant tissues but not in normal tissues. It has been reported that the survivin promoter activity is tumor-specific and makes it a good candidate for construction of gene therapy vectors. In the present study, a non-viral vector (pSURV-Mel), encoding Mel gene, was developed to evaluate its anti-tumor effect in HCC cell lines and in vivo in a mouse model of human HCC xenograft tumor. Our results showed that the survivin promoter is specifically activated in tumor cells, and the pSURV-Mel plasmid expressed Mel selectively in tumor cells and also induced cytotoxicity. Moreover, intratumoral Injection of pSURV-Mel significantly suppressed the growth of xenograft tumors. Mechanistically, pSURV-Mel induced cell death by an apoptosis-dependent pathway. All taken together, this study elucidates a relatively safe, highly effective and cancer specific gene therapy strategy for HCC. The mechanisms of non-viral vector-induced cell death which were revealed by this work will shed light on the construction of more powerful vectors for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据